Organon & Co. (NYSE:OGN – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Organon & Co. to post earnings of $0.94 per share for the quarter. Organon & Co. has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Organon & Co. (NYSE:OGN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 earnings per share. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Organon & Co. Trading Up 1.7 %
Shares of OGN stock opened at $17.46 on Tuesday. The company has a market cap of $4.49 billion, a P/E ratio of 4.49, a PEG ratio of 0.77 and a beta of 0.84. The stock has a 50 day simple moving average of $19.63 and a two-hundred day simple moving average of $20.12. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10.
Organon & Co. Announces Dividend
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the stock from $18.00 to $20.00 in a report on Friday, September 6th.
View Our Latest Research Report on OGN
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
See Also
- Five stocks we like better than Organon & Co.
- What is a Dividend King?
- Inflation Risk Rising, Key Trades Investors Are Making Now
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Oil Stocks to Watch Before Earnings Come Out
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.